Low-density lipoprotein oxidation inhibition (None.)

Low-density lipoprotein (LDL) particles can undergo oxidative modification through interactions with reactive oxygen species and transition metals such as copper and iron within arterial walls or inside lysosomes after uptake by macrophages. Oxidized forms of LDL play key roles in promoting endothelial dysfunction, inflammation, foam cell formation, plaque instability, and ultimately cardiovascular disease. The concept behind inhibiting low-density lipoprotein oxidation is therefore central to many strategies aiming at reducing cardiovascular risk—by either enhancing endogenous antioxidant defenses or administering exogenous antioxidants/drugs that prevent these modifications from occurring. However, “low-density lipoprotein oxidation inhibition” does not refer to any single protein/molecule/receptor but rather encompasses multiple pathways/processes involved in limiting this pathogenic event.

Other names

Inhibition of LDL oxidationPrevention of LDL oxidative modification

Mechanisms by which drugs inhibit LDL oxidation include: 1. Scavenging free radicals/lipid-derived radicals within the particle or associated proteins. 2. Chelating metal ions like copper that catalyze lipid peroxidation reactions in LDL particles. 3. Enhancing endogenous antioxidant capacity within plasma/arterial wall cells. 4. Reducing cholesterol content in circulating lipoproteins thereby reducing substrate for oxidation. These mechanisms are indirect; they do not involve direct antagonism/agonism at one defined protein site.